LUCIOL project illustrates the global approach endorsed by AVEROA by developing a breakthrough treatment (AVA2206) and a diagnostic test (AVA2065) for a rare renal disease with large unmet medical needs worldwide.
AVA2206 is a natural thiolhistidine that may play a major role in the early process of crystallization of renal stone. This has been demonstrated in preclinical model of cystinuria and AVA2206 has the potential to become the first line treatment for cystinuria targeting the cause leading to crystal formation.
Beyond Cystinuria, additional preclinical developments are planned to explore the full range of potential effects of AVA2206. As an inhibitor of crystal formation, AVA2206 novel mechanism of action may have high potential to be effective in various type of renal lithiasis.
AVEROA signed a research collaboration and license agreement with IdiBell, CIBER and University of Barcelona for the development to develop and exploit the product in the field of kidney and/or metabolic diseases.